Presidents Day, Black History Month, Lasker Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This column in The Cancer Letter features the latest posts to the Cancer History Project by our growing list of contributors.

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.


Upcoming

Finding the cure for childhood leukemia: On Feb. 24, a Buffalo Public Library panel featuring Jerry Yates, Mary Pinkel, and Cancer History Project editorial board member Tim Wendel.

Register in advance on Zoom.


Quote of the week

It is a great human weakness to generalize from exceptions. As scientists, we know that the best solution to a specific problem is a specific solution.

Emil J Freireich

Freireich’s Seven Laws To Protect Against Obstacles To Clinical Research
The Cancer Letter, May 14, 1976


Black History Month

jane-wright

A collection of posts celebrating the impact on oncology by Black, Indigenous, and People of Color oncologists, researchers, and advocates will continue to be available under the tag “BIPOC Impact.”


Presidents Day

These articles were highlighted on Presidents Day via @CancerHistProj on Twitter as part of a series on cancer in the White House.


Recent contributions


Is your institution a contributor to the Cancer History Project? Would you like us to tell you about the project and how you can get involved?

Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login